ChemoCentryx, Inc. Class Action Lawsuit - CCXI

(1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

In order to be eligible to join the CCXI class action lawsuit, you must have incurred a loss on shares of ChemoCentryx purchased during the class period listed above.

If you suffered a loss in ChemoCentryx during the relevant time frame or pursuant to the relevant offering(s), you have until July 6, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.